• Crescent Biopharma granted stock options covering 129,075 ordinary shares to five non-executive employees under its 2025 Employment Inducement Incentive Award Plan.
• Options carry 10-year terms with exercise price set at $18.52, equal to Nasdaq closing price on May 11, 2026.
• Vesting schedule sets 25% on first anniversary of each employee’s start date, then 1/48 monthly vesting thereafter, subject to continued service.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.